TY - JOUR
T1 - Radiolabelled proteins for positron emission tomography
T2 - Pros and cons of labelling methods
AU - Tolmachev, Vladimir
AU - Stone-Elander, Sharon
N1 - Funding Information:
Vladimir Tolmachev expresses his gratitude to the Swedish Medical Research Council (Vetenskapsrådet) for supporting his research in medical imaging and Sharon Stone-Elander gratefully acknowledges funding for radiolabelling protein probes for PET from the Swedish Medical Research Council ( K2009-53X-20033-04-2 ) and Swedish Agency for Innovation Systems (Vinnova; 2009-00179 ).
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/5
Y1 - 2010/5
N2 - Dynamic biomedical research is currently yielding a wealth of information about disease-associated molecular alterations on cell surfaces and in the extracellular space. The ability to visualize and quantify these alterations in vivo could provide important diagnostic information and be used to guide individually-optimized therapy. Biotechnology can provide proteinaceous molecular probes with highly specific target recognitions. Suitably labelled, these may be used as tracers for radionuclide-based imaging of molecular disease signatures. If the labels are positron-emitting radionuclides, the superior resolution, sensitivity and quantification capability of positron emission tomography (PET) can be exploited. Scope of review: This article discusses different approaches to labelling proteins with positron-emitting nuclides with suggestions made depending on the biological features of the tracers. Major conclusions: Factors such as matching biological and physical half-lives, availability of the nuclide, labelling yields, and influences of labelling on targeting properties (affinity, charge and lipophilicity, cellular processing and retention of catabolites) should be considered when selecting a labelling strategy for each proteinaceous tracer. General significance: The labelling strategy used can make all the difference between success and failure in a tracer application. This review emphasises chemical, biological and pharmacological considerations in labelling proteins with positron-emitting radionuclides.
AB - Dynamic biomedical research is currently yielding a wealth of information about disease-associated molecular alterations on cell surfaces and in the extracellular space. The ability to visualize and quantify these alterations in vivo could provide important diagnostic information and be used to guide individually-optimized therapy. Biotechnology can provide proteinaceous molecular probes with highly specific target recognitions. Suitably labelled, these may be used as tracers for radionuclide-based imaging of molecular disease signatures. If the labels are positron-emitting radionuclides, the superior resolution, sensitivity and quantification capability of positron emission tomography (PET) can be exploited. Scope of review: This article discusses different approaches to labelling proteins with positron-emitting nuclides with suggestions made depending on the biological features of the tracers. Major conclusions: Factors such as matching biological and physical half-lives, availability of the nuclide, labelling yields, and influences of labelling on targeting properties (affinity, charge and lipophilicity, cellular processing and retention of catabolites) should be considered when selecting a labelling strategy for each proteinaceous tracer. General significance: The labelling strategy used can make all the difference between success and failure in a tracer application. This review emphasises chemical, biological and pharmacological considerations in labelling proteins with positron-emitting radionuclides.
KW - Antibody
KW - Labelling
KW - Peptide
KW - Positron emission tomography
KW - Protein
KW - Radionuclide
UR - http://www.scopus.com/inward/record.url?scp=77950457807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950457807&partnerID=8YFLogxK
U2 - 10.1016/j.bbagen.2010.02.002
DO - 10.1016/j.bbagen.2010.02.002
M3 - Review article
C2 - 20153401
AN - SCOPUS:77950457807
VL - 1800
SP - 487
EP - 510
JO - Biochimica et Biophysica Acta - General Subjects
JF - Biochimica et Biophysica Acta - General Subjects
SN - 0006-3002
IS - 5
ER -